Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-specific cytotoxic T lymphocytes (Baylor College of Medicine)
- Development stage
- Phase 1
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EBV-specific cytotoxic T lymphocytes (EBV-CTLs) are an investigational autologous cell therapy developed by Baylor College of Medicine for the treatment of Epstein-Barr virus (EBV)-associated malignancies. The therapy involves the ex vivo expansion of a patient's own T cells, which are primed to recognize and eliminate cells expressing EBV-specific antigens, specifically Latent Membrane Protein 1 (LMP1) and Latent Membrane Protein 2 (LMP2). These viral proteins are frequently expressed in EBV-positive Hodgkin lymphoma, non-Hodgkin lymphoma, and certain plasma cell neoplasms. By restoring or enhancing the host's cellular immune response against these viral targets, the therapy aims to induce tumor regression in patients with relapsed or refractory disease. Early clinical iterations of this therapy at Baylor utilized neomycin resistance gene marking to track the persistence and localization of the infused CTLs in vivo.
- Other names
- Autologous EBV-specific cytotoxic T lymphocytesNeomycin Resistance Gene Marked EBV Specific Cytotoxic T-LymphocytesEBV-specific CTLsLMP-specific cytotoxic T lymphocytes
02
Targets
LMP1-YLLEMLWRL-HLA-A2 (Epstein-Barr virus Latent Membrane Protein 1 (LMP1) peptide YLLEMLWRL presented by HLA-A*02:01)Epstein-Barr virus latent membrane protein 2-derived peptides presented by class I human leukocyte antigen (HLA) allelesLMP1-YLQ/HLA-A2 (Epstein-Barr virus latent membrane protein 1 peptide YLQQNWWTL presented by HLA-A*02:01)
Beyond the preview
Go deeper on EBV-specific cytotoxic T lymphocytes (Baylor College of Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-specific cytotoxic T lymphocytes (Baylor College of Medicine).